Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

The grants add potential shareholder dilution through stock options and restricted stock units.

Rhea-AI Summary

Mineralys Therapeutics (Nasdaq: MLYS) granted equity inducement awards to two new non-executive employees on September 28, 2026.

The grants cover 46,430 stock option shares and 34,823 restricted stock units under the 2025 Employment Inducement Incentive Award Plan. Both vest over four years, subject to continued service. Options vest 25% on the first anniversary of September 28, 2026, then 1/48th monthly thereafter. Restricted stock units vest 25% on each of the first four anniversaries. The awards were employment inducements under Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.46,430 stock option shares create potential dilution, with four-year vesting subject to continued service.
• Minor point. Forward-looking: it has not happened yet and may not happen.34,823 restricted stock units create potential dilution, with four-year vesting subject to continued service.

Key Figures

Stock option awards: 46,430 shares Restricted stock unit awards: 34,823 shares Option vesting period: 4 years +3 more

Stock option awards

46,430 shares

Aggregate awards to two new non-executive employees

Restricted stock unit awards

34,823 shares

Aggregate awards to two new non-executive employees

Option vesting period

4 years

Subject to continued service

Initial option vesting

25%

On the first anniversary of the vesting commencement date

Subsequent option vesting

1/48th

Following each one-month period after the first anniversary; subject to continued service

Restricted stock unit vesting

25% annually for 4 years

On each of the first four anniversaries; subject to continued service

Historical Context

2 past events · Latest: Sep 21

2 events

1. Sep 21

   Inducement awards

   24h Move

   +3.9%

   Granted options for 14,880 shares and restricted stock units for 11,160 shares to one new employee.

2. Sep 09

   Inducement awards

   24h Move

   -3.9%

   Granted options for 29,760 shares and restricted stock units for 22,320 shares to two new employees.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock unit, aldosterone synthase inhibitor

2 terms

restricted stock unit financial

"restricted stock unit awards covering an aggregate of 34,823 shares"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

aldosterone synthase inhibitor medical

"highly selective aldosterone synthase inhibitor"

Aldosterone synthase inhibitors are drugs that reduce production of the hormone aldosterone, which helps control salt, water balance, and blood pressure. Think of them as turning down a faucet that feeds excess blood pressure and fluid buildup; by lowering aldosterone they can ease strain on the heart and kidneys. Investors track these drugs because trial results, regulatory approval, and safety can materially affect a developer’s revenue outlook and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 28, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering an aggregate of 46,430 shares and inducement restricted stock unit awards covering an aggregate of 34,823 shares of Mineralys common stock to two new non-executive employees.

The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option awards will vest over a four-year period, with 25% of the total shares underlying the awards vesting on the first anniversary of the awards’ vesting commencement date, September 28, 2026, and 1/48th of the total shares underlying the awards vesting following each one-month period thereafter, subject to continued service. The restricted stock unit awards will vest over a four-year period, with 25% of the shares vesting on each of the first four anniversaries of the awards’ vesting commencement date, September 28, 2026, subject to continued service. The awards were granted as an inducement material to the new non-executive employees entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Contact:

Investor Relations

investorrelations@mineralystx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many inducement equity awards did Mineralys Therapeutics grant on September 28, 2026?

Mineralys granted options covering 46,430 shares and restricted stock units covering 34,823 shares to two new non-executive employees. The grants were made under its 2025 Employment Inducement Incentive Award Plan.